Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022-Reference-Cited by-同舟云学术

Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022

Published:2022-10-27 Issue:43 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Coppi Marco¹²^ORCID,Antonelli Alberto¹²,Niccolai Claudia²,Bartolini Andrea²,Bartolini Laura¹,Grazzini Maddalena³,Mantengoli Elisabetta⁴³,Farese Alberto⁴,Pieralli Filippo⁵,Mechi Maria Teresa³,Di Pilato Vincenzo⁶¹,Giani Tommaso¹²,Rossolini Gian Maria¹²^ORCID

Affiliation:

1. Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy

2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

3. Hospital Infection Prevention and Control Unit, Florence Careggi University Hospital, Florence, Italy

4. Infectious and Tropical Diseases Unit, Florence Careggi University Hospital, Florence, Italy

5. Subintensive Care Unit, Florence Careggi University Hospital, Florence, Italy

6. Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy

Abstract

A nosocomial outbreak by cefiderocol (FDC)-resistant NDM-1-producing Klebsiella pneumoniae (NDM-Kp) occurred in a large tertiary care hospital from August 2021–June 2022 in Florence, Italy, an area where NDM-Kp strains have become endemic. Retrospective analysis of NDM-Kp from cases observed in January 2021–June 2022 revealed that 21/52 were FDC-resistant. The outbreak was mostly sustained by clonal expansion of a mutant with inactivated cirA siderophore receptor gene, which exhibited high-level resistance to FDC (MIC ≥ 32 mg/L) and spread independently of FDC exposure.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference18 articles.

1. Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria.;Bassetti;Future Microbiol,2020

2. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).;Paul;Clin Microbiol Infect,2022

3. Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in Gram-Negative MDR bacilli: molecular mechanisms and susceptibility testing.;Gaibani;Antibiotics (Basel),2022

4. Emergence of high-level cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in patients with hematologic malignancies in China.;Lan;Microbiol Spectr,2022

5. Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA.;Klein;Clin Infect Dis,2022

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study;Pediatric Infectious Disease Journal;2024-09-04

2. In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations;Microbiology Spectrum;2024-08-06

3. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05

4. Chloramphenicol activity against carbapenemase producing Enterobacterales;Journal of Global Antimicrobial Resistance;2024-06

5. Evolution of Antimicrobial Resistance in Klebsiella pneumoniae over 3 Years (2019–2021) in a Tertiary Hospital in Bucharest, Romania;Antibiotics;2024-05-10